From: Light at night and risk of breast cancer: a systematic review and dose–response meta-analysis
Breast cancer | All studies | Outdoor | Indoor | ||||||
---|---|---|---|---|---|---|---|---|---|
n | RR (95% CI) | I2 (%) | n | RR (95% CI) | I2 (%) | n | RR (95% CI) | I2 (%) | |
All women | 17 | 1.11 (1.07–1.15) | 0.0 | 7 | 1.11 (1.07–1.16) | 0.0 | 11 | 1.08 (1.00–1.17) | 6.5 |
Study design | |||||||||
Cohort/case-cohort studies | 9 | 1.11 (1.07–1.15) | 0.0 | 8 | 1.11 (1.07–1.16) | 0.0 | 4 | 1.05 (0.96–1.15) | 0. 0 |
Case–control studies | 8 | 1.11 (0.97–1.28) | 31.5 | 1 | 0.95 (0.71–1.28) | - | 7 | 1.14 (0.98–1.34) | 34.2 |
Menopausal status | |||||||||
Premenopausal | 8 | 1.16 (1.04–1.28) | 2.3 | 4 | 1.22 (1.08–1.39) | 0.0 | 4 | 1.04 (0.88–1.23) | 0.0 |
Postmenopausal | 9 | 1.07 (1.02–1.13) | 0.0 | 5 | 1.07 (1.00–1.14) | 5.9 | 4 | 1.08 (0.95–1.23) | 4.3 |
BMI | |||||||||
< 25 kg/m2 | 2 | 1.17 (1.00–1.36) | 38.9 | 2 | 1.17 (1.00–1.36) | 39.0 | - | – | - |
≥ 25 kg/m2 | 2 | 1.07 (0.87–1.32) | 53.8 | 2 | 1.07 (0.87–1.32) | 53.8 | - | – | – |
Estrogen receptor status | |||||||||
ER + | 7 | 1.09 (1.02–1.17) | 0.0 | 4 | 1.12 (0.95–1.32) | 44.8 | 3 | 1.06 (0.95–1.18) | 0.0 |
ER – | 7 | 1.07 (0.92–1.23) | 0.0 | 4 | 1.12 (0.92–1.35) | 0.0 | 3 | 1.01 (0.81–1.25) | 0.0 |
LAN/sunshine hours | |||||||||
< 2000 h | 3 | 0.99 (0.89–1.11) | 0.0 | 2 | 0.96 (0.80–1.16) | 0.0 | 1 | 1.01 (0.88–1.15) | – |
2000–3000 h | 11 | 1.12 (1.08–1.17) | 0.0 | 5 | 1.12 (1.07–1.17) | 0.0 | 7 | 1.13 (1.02–1.25) | 0.0 |
> 3000 h | 3 | 1.30 (1.11–1.52) | 15.4 | 1 | 1.47 (1.00–2.17) | – | 3 | 1.11 (0.79–1.56) | 66.3 |
Equinoctial UVB | |||||||||
0.0–0.58 W/m2 | 3 | 0.97 (0.87–1.08) | 0 .0 | 2 | 0.91 (0.76–1.09) | 0.0 | 1 | 1.01 (0.88–1.15) | – |
0.58–1.15 W/m2 | 1 | 1.27 (0.89–1.82) | – | 1 | 1.47 (1.00–2.17) | – | 1 | 1.01 (0.60–1.70) | – |
1.15–1.73 W/m2 | 13 | 1.15 (1.10–1.19) | 5.6 | 5 | 1.12 (1.07–1.17) | 0.0 | 9 | 1.20 (1.12–1.27) | 0.0 |